CHICAGO--(BUSINESS WIRE)--CytoCore (OTCBB:CYCR), the late-stage bio-pharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers, today announced improved financial guidance based on Q1-07 activities.
